

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Simkoff Maxwell</u> <hr/> (Last) (First) (Middle) 101 MISSION ST. SUITE 1050 <hr/> (Street) SAN FRANCISCO CA 94105 <hr/> (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Doma Holdings, Inc. [DOMA]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below) <u>Chief Executive Officer</u>
	3. Date of Earliest Transaction (Month/Day/Year) <u>05/06/2024</u>	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person
Rule 10b5-1(c) Transaction Indication <input type="checkbox"/> Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common stock	05/06/2024		F		5,808 ⁽¹⁾	D	\$6.05	298,408	D	
Common stock	05/07/2024		G		28,235 ⁽²⁾	D	\$0	0 ⁽³⁾	I	Maxwell Simkoff 2023 GRAT
Common stock	05/07/2024		G		28,235 ⁽²⁾	D	\$0	0 ⁽⁴⁾	I	Jennifer Saslaw 2023 GRAT
Common stock	05/07/2024		G		56,470 ⁽²⁾	A	\$0	1,857,820 ⁽⁵⁾	I	The Saslaw-Simkoff Revocable Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V		Date Exercisable	Expiration Date					

1. Name and Address of Reporting Person* <u>Simkoff Maxwell</u> <hr/> (Last) (First) (Middle) 101 MISSION ST. SUITE 1050 <hr/> (Street) SAN FRANCISCO CA 94105 <hr/> (City) (State) (Zip)
--

1. Name and Address of Reporting Person* <u>Saslaw-Simkoff Revocable Trust</u>

(Last)	(First)	(Middle)
101 MISSION ST.		
SUITE 1050		
(Street)		
SAN FRANCISCO	CA	94105
(City)		
(State)	(Zip)	

Explanation of Responses:

- As previously reported, the reporting person was granted restricted stock units ("RSUs") under the Doma Holdings, Inc.'s (the "Company") Omnibus Incentive Plan (the "Plan"), representing the right to receive shares of Company common stock in the future. The "Vesting Commencement Date" of the grant was August 3, 2023, and the grant vests as follows: 50% of the RSUs vest on the six-month anniversary of the Vesting Commencement Date and the remainder vest in 4 consecutive, equal, quarterly installments such that the award is fully vested on the 18-month anniversary of the Vesting Commencement Date; provided the reporting person is continuously employed through such date as applicable. On May 3, 2024, 16,875 shares of such RSUs vested. In connection with this vesting, 5,808 shares were withheld on May 6, 2024 to satisfy the reporting person's tax withholding obligations.
- 28,235 shares of Company common stock were previously owned by each of the Jennifer Saslaw 2023 GRAT and the Max Simkoff 2023 GRAT. These shares were distributed in the form of an annuity payment pursuant to the terms of the GRATS and subsequently transferred to The Saslaw-Simkoff Revocable Trust for no consideration.
- These shares are owned directly by the Maxwell Simkoff 2023 GRAT. The reporting person disclaims beneficial ownership except to the extent of his pecuniary interest therein.
- These shares are held for the benefit of the reporting person's wife. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
- These shares are owned directly by The Saslaw-Simkoff Revocable Trust and indirectly by Maxwell Simkoff as trustee of the trust. The reporting person disclaims beneficial ownership except to the extent of his pecuniary interest therein.

/s/ Christian Ameri, as
Attorney-in-Fact for Maxwell Simkoff 05/08/2024

/s/ Christian Ameri, as
Attorney-in-Fact for Maxwell Simkoff, Trustee 05/08/2024

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.